XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Research and Development [Abstract] |
Schedule of research and development expenses [Table Text Block] |
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Research and development expenses: |  |  |  |  |  |  |  |  |  |  |  |
SkinJect |  |  |  |  |  |  |  |  |  |  |  |
Clinical, manufacturing and regulatory activities |  | 1,268,747 |  |  | 1,011,362 |  |  | 2,011,288 |  |  | 2,453,931 |
Professional services and intellectual property |  | 96,653 |  |  | 71,561 |  |  | 145,227 |  |  | 116,678 |
Teverelix |  |  |  |  |  |  |  |  |  |  |  |
Clinical, manufacturing and regulatory activities |  | 2,927,793 |  |  | - |  |  | 3,850,023 |  |  | - |
Professional services and intellectual property |  | 46,169 |  |  | - |  |  | 78,341 |  |  | - |
Salaries and benefits |  | 568,329 |  |  | 356,641 |  |  | 1,527,207 |  |  | 875,169 |
Total research and development expenses |  | 4,907,692 |  |  | 1,439,564 |  |  | 7,612,085 |  |  | 3,445,778 |
Total general and administrative expenses |  | 6,571,097 |  |  | 4,576,524 |  |  | 12,463,781 |  |  | 7,696,584 |
Total operating expenses |  | 11,478,789 |  |  | 6,016,088 |  |  | 20,075,866 |  |  | 11,142,362 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |
Finance income |  | - |  |  | 40,004 |  |  | - |  |  | 63,870 |
Interest income (expense) |  | (205,638 | ) |  | - |  |  | (523,789 | ) |  | - |
Loss on SEPA settlements |  | - |  |  | - |  |  | (127,083 | ) |  | - |
Change in fair value of debentures |  | - |  |  | (200,000 | ) |  |  |  |  | (200,000 | )
Total other income (expense) |  | (205,638 | ) |  | (159,996 | ) |  | (650,872 | ) |  | (136,130 | )
Net loss for the period |  | (11,684,427 | ) |  | (6,176,084 | ) |  | (20,726,738 | ) |  | (11,278,492 | )

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration